Dr. Moustapha Hassan, PhD - Karolinska Institutet - Professor

Dr. Moustapha Hassan

PhD

Karolinska Institutet

Professor

Stockholm | Sweden

Main Specialties: Other

Additional Specialties: Personalized Medicine, Transplantation research

ORCID logohttps://orcid.org/0000-0003-1927-5859


Top Author

Dr. Moustapha Hassan, PhD - Karolinska Institutet - Professor

Dr. Moustapha Hassan

PhD

Introduction

Professor Moustapha Hassan is currently director of Preclinical Laboratory, the preclinical
research facility at Karolinska University Hospital, Huddinge, Sweden, as well as Professor of
Transplantation Research at Karolinska Institutet Huddinge, Stockholm, Sweden. He was
made professor in 2005, associate professor in 1994, received his doctorate from Uppsala
University in 1978 and M.Sc. in Medical-Toxicology from Alexandria University, Egypt in
1974.
Professor Hassan has extensive experience in teaching nurses, doctors, researchers and
other medical professionals about cancer medicine and hematology. He is/has been
supervisor to 46 Master, Licentiate, Doctoral and Postdoctoral students.
He is a consultant to several hospitals in Sweden and many hospitals in Europe in for
personalized treatment prior to stem cell transplantation and treatment for hematological
malignancies. His particular focus has been on increasing treatment efficacy and reducing
side effects for transplanted children. His research has resulted in several strategies to
optimize treatment with busulfan/cyclophosphamide in stem cell transplantation. Professor
Hassan developed a liposomal formulation enabling intravenous administration which is
currently undergoing clinical trials.
Professor Hassan’s current research projects focus on personalizing treatment through
genome analysis, nanomedicine and improvement in pre-transplant medicine.

Primary Affiliation: Karolinska Institutet - Stockholm , Sweden

Specialties:

Additional Specialties:


View Dr. Moustapha Hassan’s Resume / CV

Metrics

Number of Publications

265

Publications

Number of Profile Views

2696

Profile Views

Number of Article Reads

1794

Reads

Number of Citations

2315

Citations

Education

Apr 2005
Karolinska Institutet- dept of Medicine
Adjunct Professor
May 2002
Karolinska Institutet- dept of Medicine
Adjunct Lecturer
Aug 1994
Karolinska Institutet
Docent/Associate Professor
Jan 1982 - Jan 1987
Uppsala University
PhD
Jan 1987
Uppsala University, Dept of Analytical Pharmaceutical Chemistry, BMC
Ph.D.
Jan 1974
Alexandria University
MSc Toxicology - Chemistry
Jan 1974
Alexandria University
MSc Toxicology - Chemistry

Experience

Apr 2013 - Jul 2018
Karolinska Institutet
Adjunct Professor of Experimental Hematology
Oct 2012 - Feb 2014
Sahlgrenska Akademin Institutionen för neurovetenskap och fysiologi
Gästprofessor
Apr 2013
Director, Clinical Research Center, Karolinska Institutet
Apr 2013
Professor of Transplantation Research, Karolinska Institutet
Feb 2005 - Mar 2013
Karolinska Institutet
Professor of Experimental Transplantation
Oct 2012 - Feb 2012
Sahlgrenska Akademin Institutionen för neurovetenskap och fysiologi
Visiting Professor
Sep 2006
Director, Preclinical laboratory, Karolinska University Hospital
CEO
Sep 1999 - Aug 2006
Huddinge University Hospital
Head
May 1997 - Aug 1999
Huddinge Universitetssjukhus
Senior research fellow
Feb 1982 - Jan 1987
Uppsala Universitet
Post Graduate Studies
Jan 1981 - Jan 1982
Karolinska Sjukhusapoteket
Research Assistant
Jan 1981 - Jan 1982
Karolinska Sjukhusapoteket
Research Assistant
Jun 1978 - Dec 1980
Karolinska Institutet
Research Assistant
Jun 1978 - Dec 1980
Karolinska Institutet
Research Assistant
Jul 1977 - May 1978
Wales University
Research Assistant
Nov 1976 - Jun 1977
REG-105
Toxicologist
Jan 1975 - Oct 1976
Lyon Water Supply
Toxicologist
Jun 1974 - Dec 1974
World Health Organization
Apr 2013
Karolinska Institutet
Verksamhetschef
Sep 2006
Karolinska Universitetsjukhuset i Huddinge
Verksamhetschef
Karolinska University Hospital

Top co-authors

Jonas Mattsson
Jonas Mattsson

Karolinska Institutet

7
Mamoun Muhammed
Mamoun Muhammed

Royal Institute of Technology (KTH)

6
Hatem Sallam
Hatem Sallam

London School of Hygiene and Tropical Medicine

6
Behnam Sadeghi
Behnam Sadeghi

Karolinska Institutet

6
Ying Zhao
Ying Zhao

Huai'an Second People's Hospital

5
Mona Fares
Mona Fares

Laboratory Medicine

5
Olle Ringden
Olle Ringden

Karolinska Institutet

5
Marina Vita
Marina Vita

Laboratory of Hematology

5

Publications

265Publications

1794Reads

2315PubMed Central Citations

Sex-dependent behavior, neuropeptide profile and antidepressant response in rat model of depression.

Behav Brain Res 2018 10 29;351:93-103. Epub 2018 May 29.

Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address:

View Article
October 2018
32 Reads
3.030 Impact Factor

The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation.

Sci Rep 2018 May 29;8(1):8293. Epub 2018 May 29.

ECM, KFC, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
May 2018
6 Reads
1 Citation
5.080 Impact Factor

Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.

J Theor Biol 2018 Apr 11;442:1-10. Epub 2018 Jan 11.

Experimental Cancer Medicine, Clinical Research Center, Novum, Karolinska Institutet, Huddinge, 141 86 Stockholm, Sweden. Electronic address:

View Article
April 2018
7 Reads
2.120 Impact Factor

Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging.

J Nanobiotechnology 2016 Dec 19;14(1):82. Epub 2016 Dec 19.

Division of Experimental Cancer Medicine (ECM), Department of Laboratory Medicine (LABMED), Karolinska Institutet (KI), 141 86, Stockholm, Sweden.

View Article
December 2016
30 Reads
3 Citations
4.080 Impact Factor

Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice.

Int Immunopharmacol 2016 Nov 28;40:41-49. Epub 2016 Aug 28.

Experimental Cancer Medicine, Clinical Research Center, Novum, Karolinska Institutet, Huddinge, 141 86 Stockholm, Sweden; Clinical Research Center, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden. Electronic address:

View Article
November 2016
30 Reads
2.472 Impact Factor

Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation.

PLoS One 2015 6;10(11):e0141979. Epub 2015 Nov 6.

Department of Discovery Research, Medivir AB, Huddinge, Sweden.

View Article
June 2016
12 Reads
3 Citations
3.234 Impact Factor

Development and biodistribution of a theranostic aluminum phthalocyanine nanophotosensitizer.

Photodiagnosis Photodyn Ther 2016 Mar 18;13:48-57. Epub 2015 Dec 18.

Department of Materials Science, Institute of Graduate Studies and Research, University of Alexandria, Alexandria, Egypt.

View Article
March 2016
19 Reads
2.014 Impact Factor

Fluorescence labeled microbubbles for multimodal imaging.

Biochem Biophys Res Commun 2015 Aug 15;464(3):737-42. Epub 2015 Jul 15.

Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, KI, Sweden; Clinical Research Center (KFC, Novum), Karolinska University Hospital-Huddinge, Stockholm, Sweden. Electronic address:

View Article
August 2015
5 Reads
2 Citations
2.300 Impact Factor

DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line.

Biochem Biophys Res Commun 2015 Jul 27;463(3):268-74. Epub 2015 May 27.

Experimental Cancer Medicine (ECM), Clinical Research Center (KFC), Novum, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address:

View Article
July 2015
19 Reads
3 Citations
2.300 Impact Factor

Complement activation is involved in the hepatic injury caused by high-dose exposure of mice to perfluorooctanoic acid.

Chemosphere 2015 Jun 6;129:225-31. Epub 2014 Aug 6.

Department of Biochemistry and Biophysics, Arrhenius Laboratories for the Natural Sciences, Stockholm University, SE-106 91 Stockholm, Sweden; Experimental Cancer Medicine, Clinical Research Center, Novum, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden; ImmunoBioTox (IBT) AB, 16954 Solna, Sweden. Electronic address:

View Article
June 2015
11 Reads
1 Citation
3.340 Impact Factor

The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model.

Chronobiol Int 2015 Jun 4;32(5):608-14. Epub 2015 May 4.

Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet , Stockholm , Sweden .

View Article
June 2015
17 Reads
1 Citation
3.343 Impact Factor

Rat islets are not rejected by anti-islet antibodies in mice treated with costimulation blockade.

Xenotransplantation 2014 Jul-Aug;21(4):353-66. Epub 2014 May 8.

Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Human Anatomy, School of Medicine, Ahfad University for Women, Omdurman, Sudan.

View Article
May 2015
13 Reads
2.840 Impact Factor

Immunotoxicological effects of streptozotocin and alloxan: in vitro and in vivo studies.

Immunol Lett 2015 Feb 5;163(2):193-8. Epub 2015 Jan 5.

Division of Experimental Cancer Medicine, KFC, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Clinical Research Center, Novum, Karolinska University Hospital-Huddinge, Stockholm, Sweden. Electronic address:

View Article
February 2015
20 Reads
2.512 Impact Factor

Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound.

Theranostics 2014 18;4(6):604-13. Epub 2014 Mar 18.

1. Center of Biosciences, Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden; ; 3. Pancreas Research Laboratory, CLINTEC, Karolinska Institutet, Stockholm, Sweden;

View Article
January 2015
15 Reads
22 Citations
7.830 Impact Factor

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation.

PLoS One 2014 22;9(1):e86619. Epub 2014 Jan 22.

Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden ; Clinical Research Centre (Novum), Karolinska University Hospital-Huddinge, Stockholm, Sweden.

View Article
November 2014
15 Reads
1 Citation
3.234 Impact Factor

Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.

Antimicrob Agents Chemother 2014 Aug 2;58(8):4941-3. Epub 2014 Jun 2.

Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden.

View Article
August 2014
22 Reads
4 Citations
4.480 Impact Factor

Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.

Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-Serafi I, Hassan M, Ringdén O, Mattsson J, Antimicrobial agents and chemotherapy, 2014, vol. 58, no. 8, pp. 4941-4943

http://europepmc.org/abstract/med/24890587

View Article
August 2014
3 Reads

Hematologic malignancies in elderly patients.

Haematologica 2014 Jul;99(7):1124-7

Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm

View Article
July 2014
19 Reads
4 Citations
5.870 Impact Factor

Rat islets are not rejected by anti-islet antibodies in mice treated with costimulation blockade.

Diab RA, Hassan M, Tibell A, Holgersson J, Kumagai-Braesch M, Xenotransplantation, 2014, vol. 21, no. 4, pp. 353-366

http://europepmc.org/abstract/med/24807149

View Article
July 2014
6 Reads

Hematologic malignancies in elderly patients.

Hassan M, Abedi-Valugerdi M, Haematologica, 2014, vol. 99, no. 7, pp. 1124-1127

http://europepmc.org/abstract/med/24986872

View Article
July 2014
2 Reads

Biodistribution, kinetics, and biological fate of SPION microbubbles in the rat.

Int J Nanomedicine 2013 26;8:3241-54. Epub 2013 Aug 26.

Department of Clinical Science, Intervention and Technology, Division of Medical Imaging and Technology, Karolinska Institutet, and Department of Radiology, Karolinska University Hospital-Huddinge, Stockholm, Sweden ; Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
April 2014
26 Reads
8 Citations

Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging.

Biomaterials 2014 Apr 1;35(12):3885-94. Epub 2014 Feb 1.

Division of Experimental Cancer Medicine, Department of Laboratory Medicine (LABMED), Karolinska Institutet, SE-141 86 Stockholm, Sweden; Clinical Research Center, Karolinska University Hospital - Huddinge, SE-141 86 Stockholm, Sweden. Electronic address:

View Article
April 2014
19 Reads
18 Citations
8.560 Impact Factor

Activation of Wnt/β-catenin pathway in monocytes derived from chronic kidney disease patients.

PLoS One 2013 23;8(7):e68937. Epub 2013 Jul 23.

Department of Laboratory Medicine, Division of Experimental Cancer Medicine-Clinical Research Center, Karolinska Institutet, Stockholm, Sweden.

View Article
March 2014
20 Reads
5 Citations
3.234 Impact Factor

Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.

Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C, Ahmad I, Shaw PJ, Telles da Cunha JM, Schlegel PG, Hough R, Fasth A, Kentouche K, Gruhn B, Fernandes JF, Lachance S, Bredius R, Resnick IB, Belohradsky BH, Gennery A, Fischer A, Gaspar HB, Schanz U, Seger R, Rentsch K, Veys P

http://europepmc.org/abstract/med/24161820

View Article
February 2014
5 Reads

Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.

Clin Drug Investig 2014 Jan;34(1):43-52

Department of Laboratory Medicine, Experimental Cancer Medicine, Karolinska Institutet Huddinge, Novum, 141 86, Stockholm, Sweden,

View Article
January 2014
15 Reads
1 Citation
1.704 Impact Factor

Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound.

Gerling M, Zhao Y, Nania S, Norberg KJ, Verbeke CS, Englert B, Kuiper RV, Bergström A, Hassan M, Neesse A, Löhr JM, Heuchel RL, Theranostics, 2014, vol. 4, no. 6, pp. 604-613

http://europepmc.org/abstract/med/24723982

View Article
January 2014
5 Reads

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation.

El-Serafi I, Abedi-Valugerdi M, Potácová Z, Afsharian P, Mattsson J, Moshfegh A, Hassan M, PloS one, 2014, vol. 9, no. 1, pp. e86619

http://europepmc.org/abstract/med/24466173

View Article
January 2014
3 Reads

Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.

Sjöö F, El-Serafi I, Enestig J, Mattsson J, Liwing J, Hassan M, Clinical drug investigation, 2014, vol. 34, no. 1, pp. 43-52

http://europepmc.org/abstract/med/24178237

View Article
January 2014
3 Reads

The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.

PLoS One 2013 4;8(4):e60367. Epub 2013 Apr 4.

Department of Laboratory Medicine, Division of Clinical Research Center, Experimental Cancer Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
November 2013
21 Reads
2 Citations
3.234 Impact Factor

Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.

BMC Pharmacol Toxicol 2013 Sep 30;14:50. Epub 2013 Sep 30.

Experimental Cancer Medicine (ECM), Laboratory Medicine, Karolinska Institutet, 141 86, Stockholm, Sweden.

View Article
September 2013
8 Reads
2 Citations

Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion.

Bone Marrow Transplant 2013 Jun 26;48(6):843-8. Epub 2012 Nov 26.

Experimental Cancer Medicine (ECM), Department for Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
June 2013
16 Reads
3.570 Impact Factor

Sub-acute, moderate-dose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis.

Toxicol Lett 2013 May 1;219(1):1-7. Epub 2013 Mar 1.

Department of Biochemistry and Biophysics, Arrhenius Laboratories for the Natural Sciences, Stockholm University, SE-106 91 Stockholm, Sweden.

View Article
May 2013
17 Reads
1 Citation
3.262 Impact Factor

Thermostable luciferase from Luciola cruciate for imaging of carbon nanotubes and carbon nanotubes carrying doxorubicin using in vivo imaging system.

Nano Lett 2013 Apr 25;13(4):1393-8. Epub 2013 Mar 25.

Experimental Cancer Medicine, KFC, Novum, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
April 2013
26 Reads
4 Citations
13.592 Impact Factor

Thermostable luciferase from Luciola cruciate for imaging of carbon nanotubes and carbon nanotubes carrying doxorubicin using in vivo imaging system.

El-Sayed R, Eita M, Barrefelt A, Ye F, Jain H, Fares M, Lundin A, Crona M, Abu-Salah K, Muhammed M, Hassan M, Nano letters, 2013, vol. 13, no. 4, pp. 1393-1398

http://europepmc.org/abstract/med/23520995

View Article
April 2013
3 Reads

Multimodality imaging using SPECT/CT and MRI and ligand functionalized 99mTc-labeled magnetic microbubbles.

EJNMMI Res 2013 Feb 25;3(1):12. Epub 2013 Feb 25.

Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, 141 86, Stockholm, Sweden.

View Article
February 2013
21 Reads
8 Citations

Both sub-acute, moderate-dose and short-term, low-dose dietary exposure of mice to perfluorooctane sulfonate exacerbates concanavalin A-induced hepatitis.

Toxicol Lett 2013 Feb 10;217(1):67-74. Epub 2012 Dec 10.

Department of Biochemistry and Biophysics, Arrhenius Laboratories for the Natural Sciences, Stockholm University, SE-106 91 Stockholm, Sweden.

View Article
February 2013
8 Reads
3.262 Impact Factor

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.

Pharmacogenomics 2013 Jan;14(1):75-87

Experimental Cancer Medicine (ECM), Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
January 2013
7 Reads
19 Citations
3.220 Impact Factor

Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine.

J Chromatogr B Analyt Technol Biomed Life Sci 2013 Jan 10;913-914:98-105. Epub 2012 Dec 10.

Experimental Cancer Medicine, Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet Huddinge, Novum, Stockholm, Sweden.

View Article
January 2013
8 Reads
3 Citations
2.730 Impact Factor

The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.

Al-Chaqmaqchi H, Sadeghi B, Abedi-Valugerdi M, Al-Hashmi S, Fares M, Kuiper R, Lundahl J, Hassan M, Moshfegh A, PloS one, 2013, vol. 8, no. 4, pp. e60367

http://europepmc.org/abstract/med/23593203

View Article
January 2013
6 Reads

Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.

Sallam H, El-Serafi I, Meijer L, Hassan M, BMC pharmacology & toxicology, 2013, vol. 14, pp. 50

http://europepmc.org/abstract/med/24079553

View Article
January 2013
4 Reads

Multimodality imaging using SPECT/CT and MRI and ligand functionalized 99mTc-labeled magnetic microbubbles.

Barrefelt AA, Brismar TB, Egri G, Aspelin P, Olsson A, Oddo L, Margheritelli S, Caidahl K, Paradossi G, Dähne L, Axelsson R, Hassan M, EJNMMI research, 2013, vol. 3, no. 1, pp. 12

http://europepmc.org/abstract/med/23442550

View Article
January 2013
6 Reads

Biodistribution, kinetics, and biological fate of SPION microbubbles in the rat.

Barrefelt Å, Saghafian M, Kuiper R, Ye F, Egri G, Klickermann M, Brismar TB, Aspelin P, Muhammed M, Dähne L, Hassan M, International journal of nanomedicine, 2013, vol. 8, pp. 3241-3254

http://europepmc.org/abstract/med/24023513

View Article
January 2013
4 Reads

Activation of Wnt/β-catenin pathway in monocytes derived from chronic kidney disease patients.

Al-Chaqmaqchi HA, Moshfegh A, Dadfar E, Paulsson J, Hassan M, Jacobson SH, Lundahl J, PloS one, 2013, vol. 8, no. 7, pp. e68937

http://europepmc.org/abstract/med/23935909

View Article
January 2013
5 Reads

Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine.

El-Serafi I, Terelius Y, Twelkmeyer B, Hagbjörk AL, Hassan Z, Hassan M, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, vol. 913-914, pp. 98-105

http://europepmc.org/abstract/med/23286981

View Article
January 2013
4 Reads

Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

PLoS One 2012 27;7(1):e30897. Epub 2012 Jan 27.

Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
June 2012
15 Reads
3.234 Impact Factor

Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S, Nature medicine, 2011, vol. 17, no. 12, pp. 1636-1640

http://europepmc.org/abstract/med/22057347

View Article
December 2011
3 Reads

Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

Nat Med 2011 Nov 6;17(12):1636-40. Epub 2011 Nov 6.

Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.

View Article
November 2011
9 Reads
117 Citations
27.363 Impact Factor

Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.

Remberger M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Dlugosz A, Garming-Legert K, Gertow J, Gustafsson B, Hassan M, Hassan Z, Hauzenberger D, Hägglund H, Karlsson H, Klingspor L, Kumlien G, Le Blanc K, Ljungman P, Machaczka M, Malmberg KJ, Marschall HU, Mattsson J, Olsson R, Omazic B, Sairafi

http://europepmc.org/abstract/med/21620989

View Article
November 2011
3 Reads

Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.

Oral Dis 2011 Oct 1;17(7):670-6. Epub 2011 Jul 1.

Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.

View Article
October 2011
14 Reads
2 Citations
2.430 Impact Factor

Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.

Pediatr Transplant 2011 Sep 8;15(6):580-8. Epub 2011 Jul 8.

Pediatric BMT Center, Zürich University Hospital for Children, Zürich, Switzerland.

View Article
September 2011
23 Reads
9 Citations
1.630 Impact Factor

Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.

Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T, Pediatric transplantation, 2011, vol. 15, no. 6, pp. 580-588

http://europepmc.org/abstract/med/21736681

View Article
September 2011
3 Reads

Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Int J Clin Exp Pathol 2011 Aug 31;4(6):596-605. Epub 2011 Jul 31.

Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
August 2011
17 Reads
3 Citations
1.783 Impact Factor

Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Al-Hashmi S, Hassan Z, Sadeghi B, Rozell B, Hassan M, International journal of clinical and experimental pathology, 2011, vol. 4, no. 6, pp. 596-605

http://europepmc.org/abstract/med/21904635

View Article
August 2011
4 Reads

Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Clin Dev Immunol 2010 21;2010:142943. Epub 2010 Dec 21.

Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden.

View Article
June 2011
4 Reads
3 Citations
2.934 Impact Factor

The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.

Sultan Qaboos Univ Med J 2011 May 15;11(2):165-78. Epub 2011 May 15.

Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

View Article
May 2011
6 Reads
2 Citations

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro.

Eur J Immunol 2011 Apr 21;41(4):1143-53. Epub 2011 Feb 21.

Division of Clinical Immunology, Karolinska Institutet, Stockholm, Sweden.

View Article
April 2011
11 Reads
4 Citations
4.034 Impact Factor

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro.

Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringdén O, European journal of immunology, 2011, vol. 41, no. 4, pp. 1143-1153

http://europepmc.org/abstract/med/21337541

View Article
April 2011
3 Reads

Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Sadeghi B, Al-Hashmi S, Hassan Z, Rozell B, Concha H, Lundmark C, Grönvik KO, Abedi-Valugerdi M, Hassan M, Clinical & developmental immunology, 2010, vol. 2010, pp. 142943

http://europepmc.org/abstract/med/21197273

View Article
January 2010
4 Reads

Circadian variability of bilirubin in healthy men during normal sleep and after an acute shift of sleep.

Chronobiol Int 2009 Dec;26(8):1613-21

Section of Clinical Chemistry, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

View Article
December 2009
18 Reads
2 Citations
3.343 Impact Factor

Degradation of busulfan in aqueous solution.

Authors:
M Hassan H Ehrsson

J Pharm Biomed Anal 1986 ;4(1):95-101

Karolinska Pharmacy, Box 60024, S-104 01 Stockholm, Sweden.

View Article
December 2009
5 Reads
3 Citations
2.980 Impact Factor

Circadian variability of bilirubin in healthy men during normal sleep and after an acute shift of sleep.

Larsson A, Hassan M, Ridefelt P, Axelsson J, Chronobiology international, 2009, vol. 26, no. 8, pp. 1613-1621

http://europepmc.org/abstract/med/20030544

View Article
December 2009
6 Reads

Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib.

Chronobiol Int 2009 Aug;26(6):1169-88

INSERM, U 776 Rythmes biologiques et cancers, Hôp. P. Brousse, Villejuif, F-94807, France.

View Article
August 2009
13 Reads
9 Citations
3.343 Impact Factor

Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib.

Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Lévi F, Chronobiology international, 2009, vol. 26, no. 6, pp. 1169-1188

http://europepmc.org/abstract/med/19731111

View Article
August 2009
4 Reads

GVHD after chemotherapy conditioning in allogeneic transplanted mice.

Bone Marrow Transplant 2008 Dec 29;42(12):807-18. Epub 2008 Sep 29.

Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
December 2008
9 Reads
13 Citations
3.570 Impact Factor

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.

Mol Cancer Ther 2008 Sep;7(9):2713-24

Centre National de la Recherche Scientifique, Protein Phosphorylation and Human Disease Group, UPS2682, Station Biologique, B.P. 74, 29682 Roscoff cedex, Bretagne, France.

View Article
September 2008
11 Reads
7 Citations
5.683 Impact Factor

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.

Bettayeb K, Sallam H, Ferandin Y, Popowycz F, Fournet G, Hassan M, Echalier A, Bernard P, Endicott J, Joseph B, Meijer L, Molecular cancer therapeutics, 2008, vol. 7, no. 9, pp. 2713-2724

http://europepmc.org/abstract/med/18790752

View Article
September 2008
5 Reads

Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation.

Transplantation 2008 Jul;86(2):257-63

Division of Hematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article
July 2008
18 Reads
14 Citations
3.830 Impact Factor

Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.

Pharmacol Res 2008 Jul 8;58(1):32-7. Epub 2008 Jun 8.

Experimental Cancer Medicine, Clinical Research Centre, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden.

View Article
July 2008
36 Reads
10 Citations
4.410 Impact Factor

Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.

Sallam H, Jimenez P, Song H, Vita M, Cedazo-Minguez A, Hassan M, Pharmacological research : the official journal of the Italian Pharmacological Society, 2008, vol. 58, no. 1, pp. 32-37

http://europepmc.org/abstract/med/18588979

View Article
July 2008
4 Reads

Dynamics of fat cell turnover in humans.

Nature 2008 Jun 4;453(7196):783-7. Epub 2008 May 4.

Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.

View Article
June 2008
56 Reads
478 Citations
42.351 Impact Factor

A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant 2008 May 7;41(9):785-90. Epub 2008 Jan 7.

Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden.

View Article
May 2008
19 Reads
3 Citations
3.570 Impact Factor

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.

Bone Marrow Transplant 2008 May 28;41(10):895-904. Epub 2008 Jan 28.

Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet and Clinical Research Center Novum, Karolinska University Hospital-Huddinge, Stockholm, Sweden.

View Article
May 2008
3 Reads
4 Citations
3.570 Impact Factor

Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.

Bone Marrow Transplant 2008 Apr 17;41(7):621-5. Epub 2007 Dec 17.

Department of Oncology and Immunology, The Queen Silvia Children's Hospital, Göteborg, Sweden.

View Article
April 2008
11 Reads
3.570 Impact Factor

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.

Exp Hematol 2008 Feb;36(2):149-57

Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.

View Article
February 2008
8 Reads
15 Citations
2.480 Impact Factor

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.

Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekström TJ, Zhivotovsky B, Hellström-Lindberg E, Experimental hematology, 2008, vol. 36, no. 2, pp. 149-157

http://europepmc.org/abstract/med/18206726

View Article
February 2008
4 Reads

Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient.

Hum Reprod 2008 Jan 2;23(1):139-43. Epub 2007 Nov 2.

Division of Obstetrics and Gynecology, Department of Clinical Science, Intervention and Technology, Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden.

View Article
January 2008
24 Reads
22 Citations
4.570 Impact Factor

The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats.

Clin Cancer Res 2007 Jul;13(14):4218-24

Experimental Cancer Medicine, Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden.

View Article
July 2007
8 Reads
1 Citation
8.722 Impact Factor

The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats.

Afsharian P, Terelius Y, Hassan Z, Nilsson C, Lundgren S, Hassan M, Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, vol. 13, no. 14, pp. 4218-4224

http://europepmc.org/abstract/med/17634551

View Article
July 2007
2 Reads

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M, Nature medicine,

http://europepmc.org/abstract/med/16582916

View Article
April 2006
6 Reads

Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.

Basic Clin Pharmacol Toxicol 2006 Feb;98(2):197-200

Department of Pharmacology, Gazi University, Medical Faculty, Ankara, Turkey.

View Article
February 2006
9 Reads
4 Citations
2.380 Impact Factor

Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.

Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U, Basic & clinical pharmacology & toxicology, 2006, vol. 98, no. 2, pp. 197-200

http://europepmc.org/abstract/med/16445595

View Article
February 2006
3 Reads

Myeloablative and immunosuppressive properties of treosulfan in mice.

Exp Hematol 2006 Jan;34(1):115-21

Laboratory of Hematology, Karolinska Hematology Center, Karolinska University Hospital, Huddinge, Stockholm, Sweden.

View Article
January 2006
35 Reads
7 Citations
2.480 Impact Factor

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Eur J Pharm Sci 2006 Jan 23;27(1):54-61. Epub 2005 Sep 23.

Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, SE 141-86 Stockholm, Sweden.

View Article
January 2006
14 Reads
25 Citations
3.350 Impact Factor

A pharmacodynamic study of 5-azacytidine in the P39 cell line.

Exp Hematol 2006 Jan;34(1):35-43

Department of Medicine, Division of Hematology, Karolinska University Hospital-Huddinge, Karolinska Institute, Stockholm, Sweden.

View Article
January 2006
20 Reads
5 Citations
2.480 Impact Factor

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Xie H, Griskevicius L, Ståhle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, Hassan M, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2006, vol. 27, no. 1, pp. 54-61

http://europepmc.org/abstract/med/16183265

View Article
January 2006
3 Reads

Myeloablative and immunosuppressive properties of treosulfan in mice.

Sjöö F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, Aschan J, Concha H, Gaughan U, Hassan M, Experimental hematology, 2006, vol. 34, no. 1, pp. 115-121

http://europepmc.org/abstract/med/16413398

View Article
January 2006
3 Reads

A pharmacodynamic study of 5-azacytidine in the P39 cell line.

Khan R, Aggerholm A, Hokland P, Hassan M, Hellström-Lindberg E, Experimental hematology, 2006, vol. 34, no. 1, pp. 35-43

http://europepmc.org/abstract/med/16413389

View Article
January 2006
3 Reads

Myeloablative and immunosuppressive properties of treosulfan in mice

Experimental Hematology

OBJECTIVE: Treosulfan is a prodrug with a specific clinical activity in ovarian carcinoma and other solid tumors. Due to its myeloablative and immunosuppressive effects, its use in conditioning regimens prior to allogeneic stem cell treatment (SCT) has been proposed. In the present preclinical study, myeloablative as well as immunosuppressive properties of treosulfan were compared with those of busulfan and cyclophosphamide. METHODS: Three groups of BALB/c mice were treated with treosulfan, cyclophosphamide, or busulfan at sublethal doses that maintained survival without bone marrow support. The control group was left untreated. At different intervals, colony-forming unit granulocyte macrophage assay was performed on marrow cells. Additionally, immunological analyses were performed using spleen cells. RESULTS: We found that treosulfan and busulfan induced a high and persisting degree of myeloablation, as compared with cyclophosphamide. Moreover, treosulfan was more effective in depletion of splenic B and T cells in comparison with busulfan and cyclophosphamide. Furthermore, T cells isolated from the spleens of treosulfan- or busulfan-treated mice were not responsive to allogeneic cells compared with that observed in controls and cyclophosphamide-treated mice. Treatment with treosulfan induced only interleukin-2 production in spleen cells for a short time and had no significant effect on synthesis of tumor necrosis factor-alpha and/or interferon-gamma as compared with that observed in splenic T cells isolated from mice treated with either busulfan or cyclophosphamide. CONCLUSION: Our findings suggest that treosulfan possesses both myeloablative and immunosuppressive properties and may be used as a single agent for conditioning prior to bone marrow transplantation.

View Article
January 2006
14 Reads

The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.

Eur J Haematol 2005 Sep;75(3):206-11

Department of Medicine, Division of Hematology, Karolinska Institutet, Huddinge, Stockholm, Sweden.

View Article
September 2005
18 Reads
1 Citation
2.070 Impact Factor

The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.

Afsharian P, Möllgård L, Hassan Z, Xie H, Kimby E, Hassan M, European journal of haematology, 2005, vol. 75, no. 3, pp. 206-211

http://europepmc.org/abstract/med/16104876

View Article
September 2005
3 Reads

Stability, pKa and plasma protein binding of roscovitine.

J Chromatogr B Analyt Technol Biomed Life Sci 2005 Jul;821(1):75-80

Department of Medicine, Division of Hematology, Laboratory of Hematology, Karolinska University Hospital, Huddinge S-14186, Sweden.

View Article
July 2005
21 Reads
6 Citations
2.730 Impact Factor

Stability, pKa and plasma protein binding of roscovitine.

Vita M, Abdel-Rehim M, Nilsson C, Hassan Z, Skansen P, Wan H, Meurling L, Hassan M, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, vol. 821, no. 1, pp. 75-80

http://europepmc.org/abstract/med/15894521

View Article
July 2005
5 Reads

Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta.

Transplantation 2005 Jun;79(11):1607-14

Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden.

View Article
June 2005
22 Reads
90 Citations
3.830 Impact Factor

Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta.

Le Blanc K, Götherström C, Ringdén O, Hassan M, McMahon R, Horwitz E, Anneren G, Axelsson O, Nunn J, Ewald U, Nordén-Lindeberg S, Jansson M, Dalton A, Aström E, Westgren M, Transplantation, 2005, vol. 79, no. 11, pp. 1607-1614

http://europepmc.org/abstract/med/15940052

View Article
June 2005
3 Reads

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat.

Eur J Pharm Sci 2005 May;25(1):91-103

Department of Medicine, Division of Hematology, Karolinska Institute, Sweden.

View Article
May 2005
19 Reads
13 Citations
3.350 Impact Factor

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat.

Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Sidén A, Sidén M, Pettersson T, Hassan M, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2005, vol. 25, no. 1, pp. 91-103

http://europepmc.org/abstract/med/15854805

View Article
May 2005
4 Reads

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.

Exp Hematol 2005 Mar;33(3):380-7

Laboratory of Hematology, Division of Hematology, Department of Medicine Karolinska University Hospital, Huddinge, Stockholm, Sweden.

View Article
March 2005
19 Reads
3 Citations
2.480 Impact Factor

Development and validation of a liquid chromatography and tandem mass spectrometry method for determination of roscovitine in plasma and urine samples utilizing on-line sample preparation.

J Chromatogr B Analyt Technol Biomed Life Sci 2005 Mar;817(2):303-7

Department of Medicine, Division of Hematology, Laboratory of Hematology, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden.

View Article
March 2005
21 Reads
3 Citations
2.730 Impact Factor

Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice.

Immunology 2005 Mar;114(3):428-37

Department of Immunology, the Wenner-Gren Institute, Arrhenius Laboratories for the Natural Sciences, Stockholm University, Stockholm, Sweden.

View Article
March 2005
27 Reads
10 Citations
3.800 Impact Factor

Development and validation of a liquid chromatography and tandem mass spectrometry method for determination of roscovitine in plasma and urine samples utilizing on-line sample preparation.

Vita M, Skansen P, Hassan M, Abdel-Rehim M, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, vol. 817, no. 2, pp. 303-307

http://europepmc.org/abstract/med/15686999

View Article
March 2005
5 Reads

Lung epithelial cells and type II pneumocytes of donor origin after allogeneic hematopoietic stem cell transplantation.

Transplantation 2004 Jul;78(1):154-7

Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Stockholm, Sweden.

View Article
July 2004
14 Reads
21 Citations
3.830 Impact Factor

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Lancet 2004 May;363(9419):1439-41

Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden.

View Article
May 2004
19 Reads
570 Citations
45.220 Impact Factor

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O, Lancet, 2004, vol. 363, no. 9419, pp. 1439-1441

http://europepmc.org/abstract/med/15121408

View Article
May 2004
4 Reads

Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat.

J Pharm Biomed Anal 2004 Feb;34(2):425-31

Department of Neurology, R-54, Huddinge University Hospital, Karolinska Institute, S-141 86 Stockholm, Sweden.

View Article
February 2004
14 Reads
3 Citations
2.980 Impact Factor

Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat.

Vita M, Meurling L, Pettersson T, Cruz-Sidén M, Sidén A, Hassan M, Journal of pharmaceutical and biomedical analysis, 2004, vol. 34, no. 2, pp. 425-431

http://europepmc.org/abstract/med/15013157

View Article
February 2004
3 Reads

On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS).

Ther Drug Monit 2003 Jun;25(3):400-6

AstraZeneca R & D Södertälje, DMPK and Bioanalytical Chemistry, Södertälje, Sweden.

View Article
June 2003
21 Reads
1 Citation
2.380 Impact Factor

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Eur J Clin Pharmacol 2003 Jun 9;59(2):103-9. Epub 2003 Apr 9.

Department of Medical Laboratory Sciences and Technology, Karolinska Institutet at Huddinge University Hospital, 14186 Stockholm, Sweden.

View Article
June 2003
17 Reads
10 Citations
2.970 Impact Factor

Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line.

Eur J Pharmacol 2002 Aug;449(3):197-205

Division of Clinical Pharmacology, Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden.

View Article
August 2002
10 Reads
2.532 Impact Factor

The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.

Bone Marrow Transplant 2002 Aug;30(3):141-7

Department of Medicine, Division of Hematology, Karolinska Institutet at Huddinge University Hospital, Sweden.

View Article
August 2002
14 Reads
5 Citations
3.570 Impact Factor

Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line.

Xie HJ, Lundgren S, Broberg U, Finnström N, Rane A, Hassan M, European journal of pharmacology, 2002, vol. 449, no. 3, pp. 197-205

http://europepmc.org/abstract/med/12167460

View Article
August 2002
3 Reads

Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma.

Ther Drug Monit 2002 Jun;24(3):405-9

Department of Medicine, Division of Hematology, Laboratory of Hematology, KFC Novum, Karolinska Institutet, Huddinge University Hospital, 141 86 Stockholm, Sweden.

View Article
June 2002
17 Reads
2 Citations
2.380 Impact Factor

Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma.

Griskevicius L, Meurling L, Hassan M, Therapeutic drug monitoring, 2002, vol. 24, no. 3, pp. 405-409

http://europepmc.org/abstract/med/12021633

View Article
June 2002
4 Reads

Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat.

Br J Cancer 2001 Dec;85(12):2004-9

Childhood Cancer Research Unit, Dept of Women's and Children's Health, Karolinska Institutet, Karolinska Hospital, S-171 76 Stockholm, Sweden.

View Article
December 2001
7 Reads
4 Citations
4.840 Impact Factor

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.

Bone Marrow Transplant 2001 Oct;28(7):657-64

Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Faculty of Pharmacy, Uppsala University, S-751 25 Uppsala, Sweden.

View Article
October 2001
8 Reads
7 Citations
3.570 Impact Factor

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro.

Leukemia 2001 Aug;15(8):1240-7

Department of Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden.

View Article
August 2001
10 Reads
5 Citations
10.431 Impact Factor

Pharmacokinetics of liposomal busulphan in man.

Bone Marrow Transplant 2001 Mar;27(5):479-85

Department of Medicine, Division of Hematology, Karolinska Institutet at Huddinge University Hospital, Sweden.

View Article
March 2001
14 Reads
2 Citations
3.570 Impact Factor

Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study.

J Lipid Res 2001 Jan;42(1):70-8

Division of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, SE-141 86 Huddinge, Sweden.

View Article
January 2001
9 Reads
14 Citations
4.421 Impact Factor

The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo.

Med Pediatr Oncol 2001 Jan;36(1):127-31

Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden.

View Article
January 2001
13 Reads
8 Citations

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.

Leukemia 2000 Nov;14(11):1954-9

Department of Haematology, Hammersmith Hospital, ICSM, London, UK.

View Article
November 2000
5 Reads
3 Citations
10.431 Impact Factor

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

Ther Drug Monit 2000 Aug;22(4):383-5

Department of Medicine, Huddinge University Hospital, Sweden.

View Article
August 2000
5 Reads
4 Citations
2.380 Impact Factor

Capillary gas chromatography of trichlorophenols using ammonia as carrier gas

Journal of High Resolution Chromatography

View Article
February 2000
18 Reads

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Br J Clin Pharmacol 1999 Nov;48(5):669-77

Department of Hematology, Huddinge University Hospital, Huddinge; Department of Medical Laboratory Science and Technology, Division of Clinical Pharmacology, Huddinge University Hospital, Huddinge; Karolinska Pharmacy, Sweden.

View Article
November 1999
4 Reads
13 Citations
3.880 Impact Factor

Biodistribution of liposomal 131I-VIP in rat using gamma camera.

Nucl Med Biol 1999 Nov;26(8):931-6

Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

View Article
November 1999
6 Reads
1 Citation
2.412 Impact Factor

The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo.

Pediatr Res 1999 Sep;46(3):328-32

Childhood Cancer Research Unit, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.

View Article
September 1999
4 Reads
4 Citations
2.314 Impact Factor

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.

Eur J Haematol 1999 Sep;63(3):163-70

Karolinska Pharmacy, Stockholm, Sweden.

View Article
September 1999
10 Reads
1 Citation
2.070 Impact Factor

The role of busulfan in bone marrow transplantation

Medical oncology

View Article
September 1999
11 Reads

In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.

Life Sci 1999 ;65(2):165-74

Karolinska Pharmacy, and Clinical Neuroscience Department, Karolinska Hospital and Institute, Stockholm, Sweden.

View Article
July 1999
14 Reads
6 Citations
2.702 Impact Factor

In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera.

Nucl Med Biol 1999 May;26(4):413-20

Karolinska Pharmacy, Stockholm, Sweden.

View Article
May 1999
5 Reads
7 Citations
2.412 Impact Factor

Liposomal busulphan: bioavailability and effect on bone marrow in mice.

Bone Marrow Transplant 1998 Nov;22(9):913-8

Karolinska Pharmacy, Stockholm, Sweden.

View Article
November 1998
5 Reads
1 Citation
3.570 Impact Factor

Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.

Cancer Chemother Pharmacol 1998 ;42(6):471-8

Department of Clinical Pharmacology, Huddinge University Hospital, Sweden.

View Article
November 1998
15 Reads
2 Citations
2.770 Impact Factor

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.

Bone Marrow Transplant 1997 Dec;20(11):909-13

Department of Hematology, Huddinge University Hospital, Karolinska Institute, Sweden.

View Article
December 1997
5 Reads
7 Citations
3.570 Impact Factor

Somatostatin in neuroblastoma and ganglioneuroma.

Eur J Cancer 1997 Oct;33(12):2084-9

Dept. of Woman and Child Health, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.

View Article
October 1997
2 Reads
4 Citations
5.420 Impact Factor

Synthesis and in vivo biodistribution of tyrosine kinase inhibitor, [methoxy-11C]PD 153035

Journal of Labelled Compounds and Radiopharmaceuticals

View Article
February 1997
15 Reads

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.

Bone Marrow Transplant 1996 Nov;18(5):843-50

Karolinska Pharmacy, Research Department, Stockholm, Sweden.

View Article
November 1996
10 Reads
5 Citations
3.570 Impact Factor

Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver.

Eur J Drug Metab Pharmacokinet 1995 Jul-Sep;20(3):225-32

Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden.

View Article
October 1996
7 Reads
1 Citation
1.312 Impact Factor

Infection-associated hemophagocytic syndrome complicated by infectious lymphoproliferation: a case report.

Pediatr Hematol Oncol 1996 Mar-Apr;13(2):143-50

2nd Department of Pediatrics, University Hospital, Motol, Prague Czech Republic.

View Article
September 1996
6 Reads
1 Citation
0.963 Impact Factor

One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.

Int Psychogeriatr 1995 ;7(1):75-83

Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.

View Article
December 1995
4 Reads
1.934 Impact Factor

Effect of ammonia on the response of the electron capture detector (ECD)

Journal of high resolution chromatography

View Article
December 1995
17 Reads

Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.

Bone Marrow Transplant 1995 Jun;15(6):869-71

Department of Medicine, Huddinge University Hospital, Sweden.

View Article
June 1995
3 Reads
1 Citation
3.570 Impact Factor

Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.

Int Clin Psychopharmacol 1994 ;9(4):263-70

Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.

View Article
March 1995
13 Reads
1 Citation
2.460 Impact Factor

Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.

Blood 1994 Dec;84(12):4078-87

Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden.

View Article
December 1994
5 Reads
9 Citations
10.452 Impact Factor

Busulfan bioavailability.

Blood 1994 Oct;84(7):2144-50

Research Department, Huddinge Hospital, Stockholm, Sweden.

View Article
October 1994
3 Reads
14 Citations
10.452 Impact Factor

Effect of Ammonia Carrier Gas on the Response of the Flame Ionization Detector

Journal of high resolution chromatography

View Article
October 1994
21 Reads

In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.

Nucl Med Biol 1994 Aug;21(6):865-72

Karolinska Pharmacy, Research Department, Karolinska Institute, Stockholm, Sweden.

View Article
August 1994
3 Reads
5 Citations
2.412 Impact Factor

Clinical experiences and biochemical findings with tacrine (THA).

Acta Neurol Scand Suppl 1993 ;149:36-8

Department of Psychiatry and Psychology, Karolinska-Institute and Hospital, Stockholm, Sweden.

View Article
April 1994
2 Reads
1 Citation

Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Cancer Chemother Pharmacol 1993 ;33(3):181-6

Karolinska Pharmacy, Stockholm, Sweden.

View Article
February 1994
4 Reads
12 Citations
2.770 Impact Factor

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.

J Clin Oncol 1992 Oct;10(10):1514-8

Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden.

View Article
October 1992
10 Reads
8 Citations
18.430 Impact Factor

In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient.

Cancer Chemother Pharmacol 1992 ;30(2):81-5

Karolinska Pharmacy, Stockholm, Sweden.

View Article
July 1992
6 Reads
5 Citations
2.770 Impact Factor

11C-labeling of busulphan.

Int J Rad Appl Instrum A 1991 ;42(11):1055-9

Karolinska Pharmacy, Stockholm, Sweden.

View Article
June 1992
3 Reads

Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.

Cancer Chemother Pharmacol 1991 ;28(2):130-4

Karolinska Pharmacy, Stockholm.

View Article
August 1991
2 Reads
10 Citations
2.770 Impact Factor

Capillary Gas-Chromatography of Chlorophenols with Ammonia as Carrier Gas

ournal of High Resolution Chromatography

View Article
April 1991
16 Reads

11C-labeling of busulphan

International journal of radiation applications and instrumentation. Part A. Applied radiation and isotopes

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1667312

View Article
January 1991
3 Reads

Capillary Gas-Chromatography of Amines with Ammonia as Carrier Gas

ournal of High Resolution Chromatography

View Article
April 1990
17 Reads

Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Eur J Clin Pharmacol 1989 ;36(5):525-30

Karolinska Pharmacy, Stockholm, Sweden.

View Article
September 1989
13 Reads
12 Citations
2.970 Impact Factor

Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.

Eur J Drug Metab Pharmacokinet 1988 Oct-Dec;13(4):301-5

Karolinska Pharmacy, Stockholm, Sweden.

View Article
June 1989
3 Reads
2 Citations
1.312 Impact Factor

Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy.

Bone Marrow Transplant 1989 Jan;4(1):113-4

Karolinska Pharmacy, Stockholm, Sweden.

View Article
January 1989
5 Reads
3 Citations
3.570 Impact Factor

Metabolism of 14C-busulfan in isolated perfused rat liver.

Authors:
M Hassan H Ehrsson

Eur J Drug Metab Pharmacokinet 1987 Jan-Mar;12(1):71-6

View Article
September 1987
8 Reads
7 Citations
1.312 Impact Factor

Urinary metabolites of busulfan in the rat.

Authors:
M Hassan H Ehrsson

Drug Metab Dispos 1987 May-Jun;15(3):399-402

View Article
August 1987
4 Reads
5 Citations
3.252 Impact Factor

Binding of busulfan to plasma proteins and blood cells.

Authors:
H Ehrsson M Hassan

J Pharm Pharmacol 1984 Oct;36(10):694-6

View Article
October 1984
2 Reads
3 Citations
2.161 Impact Factor

Determination of busulfan in plasma by GC-MS with selected-ion monitoring.

Authors:
H Ehrsson M Hassan

J Pharm Sci 1983 Oct;72(10):1203-5

View Article
October 1983
4 Reads
1 Citation
2.590 Impact Factor

Gas chromatographic determination of busulfan in plasma with electron-capture detection.

Authors:
M Hassan H Ehrsson

J Chromatogr 1983 Oct;277:374-80

View Article
October 1983
11 Reads
2 Citations

Busulfan kinetics.

Clin Pharmacol Ther 1983 Jul;34(1):86-9

View Article
July 1983
5 Reads
6 Citations
7.903 Impact Factor

Top co-authors

Jonas Mattsson
Jonas Mattsson

Karolinska Institutet

7
Mamoun Muhammed
Mamoun Muhammed

Royal Institute of Technology (KTH)

6
Hatem Sallam
Hatem Sallam

London School of Hygiene and Tropical Medicine

6
Behnam Sadeghi
Behnam Sadeghi

Karolinska Institutet

6
Ying Zhao
Ying Zhao

Huai'an Second People's Hospital

5
Mona Fares
Mona Fares

Laboratory Medicine

5
Olle Ringden
Olle Ringden

Karolinska Institutet

5
Marina Vita
Marina Vita

Laboratory of Hematology

5